Fund category guide
Best healthcare funds in India: what they own, and what to expect from them
Healthcare funds hold two businesses under one label: generic drug exporters selling into America, and hospitals and diagnostics chains selling to Indians. The first is a margin cycle set abroad; the second is domestic and steady. Which mix you buy decides what you get.
Key takeaways
- Healthcare funds are SEBI sectoral or thematic schemes: at least 80% of assets must stay in the healthcare theme.
- The label covers two different businesses — export generics on a global pricing cycle, and domestic hospitals and diagnostics.
- Demand is inelastic, so drawdowns are shallower than cyclical sectors: 30-40% rather than 45-55%.
- The dominant risk is regulatory: plant inspections, approval delays and price control orders change earnings by decision, not by market.
- Hospitals and diagnostics trade at high multiples, so a growth miss costs more than the earnings shortfall suggests.
- Taxed like any equity fund: 12.5% long-term above ₹1.25 lakh a year, 20% short-term.
What is a healthcare mutual fund?
A healthcare fund is an open-ended equity scheme in SEBI’s sectoral and thematic category, so at least 80% of assets must sit in the sector named in the mandate. For healthcare that spans drug makers, contract manufacturers and research organisations, hospital chains, diagnostics laboratories, medical device firms and health insurers, depending on how widely the fund house reads the theme.
The split inside the portfolio matters more than the label. Generic exporters earn a large share of revenue in the United States, where pricing has been under pressure for a decade and where a single regulatory observation on a plant can stop a product line. Domestic formulations, hospitals and diagnostics are the opposite: rupee revenue, steady volume growth, pricing that moves with income rather than with a foreign buyer’s procurement policy.
Two consequences follow. Healthcare is defensive in demand but not in valuation — hospital and diagnostics stocks have carried high multiples for years, so a growth disappointment is expensive. And the sector’s biggest risk is administrative: an inspection outcome, a price control order, or a change in what a foreign regulator will approve.
Ways to own the healthcare theme
“Healthcare fund” covers four fairly different mandates. Pick the one whose driver you actually want exposure to.
The export engine: Indian companies making off-patent drugs for the United States, Europe and emerging markets. Earnings follow approvals, competition and plant compliance.
US generics
High volume, price-eroding business. A complex or limited-competition launch can transform a year’s profit.
Price erosionComplex generics
Injectables, inhalers and specialty products with fewer competitors and better margins. Harder to make, harder to approve.
Higher marginDomestic formulations
Branded generics sold to Indian doctors. Steady double-digit growth, rupee revenue, no FDA exposure.
SteadyEmerging markets
Africa, Latin America and Southeast Asia. Growth is good; currency and payment risk are real.
FX riskWhich are the best healthcare funds in India?
Look at the export-versus-domestic split before the return column. A fund weighted to US generics behaves like a global margin cycle; one weighted to hospitals and diagnostics behaves like Indian consumption. After that the screen is the usual one: a record through a full cycle, rolling returns against the Nifty Healthcare index, a reasonable expense ratio, and a manager who was there for the record you are buying.
The table below is ranked on three-year returns and refreshed from live scheme data. Judge any fund against the Nifty Healthcare TRI rather than against the Nifty 50.
| Fund | AUM | 1Y | 3Y | 3Y volatility | Expense |
|---|---|---|---|---|---|
| SBI Healthcare Opportunities Reg Gr | ₹5,796 Cr | 20.20% | 22.97% | 14.37% | 2.00% |
| UTI Healthcare Reg Gr | ₹1,444 Cr | 15.37% | 22.91% | 15.92% | 2.22% |
| LIC MF Healthcare Reg Gr | ₹103 Cr | 15.08% | 21.19% | 15.86% | 2.72% |
| Mirae Asset Healthcare Reg Gr | ₹3,442 Cr | 17.90% | 21.10% | 16.11% | 1.65% |
| ICICI Pru Pharma Healthcare Diag Gr | ₹6,996 Cr | 5.48% | 20.92% | 16.12% | 2.09% |
| ABSL Pharma & Healthcare Reg Gr | ₹1,103 Cr | 15.93% | 20.17% | 15.26% | 1.90% |
| DSP Healthcare Fund Reg Gr | ₹3,639 Cr | 13.75% | 20.13% | 14.89% | 2.02% |
| Quant Healthcare Reg Growth | ₹397 Cr | 16.70% | 18.94% | 18.13% | 3.14% |
| Category average | — | 16.11% | 20.60% | 16.08% | — |
Returns annualised (CAGR) for periods over one year, as reported for the plan listed. Expense ratios shown are for that plan; the direct plan of the same scheme carries a lower one. Past performance does not indicate future returns.
How do you choose a healthcare fund?
Five checks, in the order they matter. The first one decides whether you are buying an export cycle or domestic demand.
Check the export-versus-domestic split
A portfolio weighted to US generics rises and falls with price erosion, approvals and plant compliance. One weighted to hospitals and diagnostics tracks Indian income growth. Both are called healthcare funds, and in a given year one can beat the other by fifteen percentage points.
Screen: read the top ten holdings, not the fund name
A record through the 2019-2022 swing
Pharma went from years of de-rating to a pandemic surge to a sharp correction inside four years. A fund that lived through all of it shows you how the manager handled both the compliance problems and the euphoria.
Screen: 7+ years, or accept an untested fund knowingly
Concentration and single-stock risk
The liquid healthcare universe is a few dozen names, so the top ten usually carry 55-70%. Because a single plant inspection can halve a company’s earnings, position size in this sector matters more than in most.
Screen: no single holding above 12-14%
Expense ratio against the index option
A Nifty Pharma or Healthcare index fund gives you the sector for about 0.35%. Several active funds in the category charge over 1.1%. In a sector where dispersion between companies is genuinely wide, active can earn its fee — but check that this fund has.
Screen: direct plan under 1.0%, compared to an index option
Overlap with what you already own
Diversified and index funds hold 5-7% in pharma already, and several flexi cap managers have been overweight the sector for years. Check the overlap before adding a concentrated version of the same names.
Screen: overlap with core funds under 25%
Healthcare vs FMCG vs diversified equity
Healthcare and FMCG are both called defensive, and both are. The difference is where the risk sits: regulation and foreign pricing on one side, input costs and competition on the other.
| Attribute | Healthcare fund | FMCG fund | Diversified equity |
|---|---|---|---|
| What it holds | Pharma, hospitals, diagnostics, min 80% | Staples, personal care, beverages | All sectors at index weight |
| Main driver | US pricing, approvals, domestic volumes | Volume growth, input costs, rural demand | Broad corporate earnings |
| Biggest risk | Regulatory action on a plant or a price | Margin squeeze and new competition | Market-wide de-rating |
| Typical volatility | Moderate to high | Low to moderate | Moderate |
| Worst-case drawdown | 30-40% | 25-35% | 25-35% |
| Role in a portfolio | Defensive satellite, 5-10% | Defensive satellite, 5-10% | Core holding |
What would an SIP in a healthcare fund grow to?
Set a monthly amount, a horizon and a return assumption. The third slider deserves restraint: the category’s recent three-year numbers came off a very weak 2022 base, and healthcare’s long-run return has been closer to mid-teens.
Worked example: a ₹10,000 monthly SIP held for 15 years at 13% a year is ₹18,00,000 invested across 180 instalments. That projects to ₹55,56,813, of which ₹37,56,813 is estimated gains. The figure assumes a constant return; real healthcare returns vary year to year and can be negative, so treat it as arithmetic, not a forecast.
- Total invested
- ₹18,00,000
- Estimated gains
- ₹37,56,813
- After 12.5% LTCG tax
- ₹50,87,211
A projection, not a promise. Healthcare returns are steadier than cyclical sectors but still arrive unevenly.
Who should invest in healthcare funds?
- You already hold a diversified equity core and want a defensive tilt with a genuine long-term demand story behind it.
- You accept that returns here are event-driven — approvals, resolutions, launches — rather than smooth quarter to quarter.
- You can hold a 5-10% satellite position for seven years or more through at least one regulatory scare.
- You want exposure to Indian healthcare capacity growth, which is under-built relative to demand.
And who should skip it
- This would be your first equity fund. Start with a diversified or index fund and build the core.
- You would sell on the news of a warning letter. That is exactly when a healthcare fund tends to be cheapest.
- You need the money inside five years, or you would sell after a 35% fall.
What are the risks?
Regulatory action is the defining risk
A USFDA warning letter or import alert on a single plant can stop supply and remove a large share of a company’s profit until resolved. These decisions arrive without warning and are not predictable from the financials.
US price erosion
Generic prices in America fall almost every year as buyers consolidate and competitors enter. Growth has to come from new approvals and complex products faster than the base erodes.
Domestic price control
A large share of Indian formulation volumes falls under price ceilings, and additions to the essential medicines list can cut realisations by administrative order.
High multiples in services
Hospital and diagnostics stocks trade at premium valuations on the strength of their growth. A single weak quarter of occupancy or test volumes gets punished hard.
Concentration is the design
The 80% rule means the manager cannot leave the sector when it de-rates. Stock selection can soften a bad pharma cycle; it cannot avoid one.
How are healthcare funds taxed?
Healthcare funds are equity-oriented schemes, so equity capital gains rules apply — the same as a large cap or flexi cap fund. Tax is triggered on redemption or switch, not on notional growth.
Held 12 months or less
20%
Short-term capital gains, taxed at a flat 20% regardless of your income slab.
Held over 12 months
12.5%
Long-term capital gains, taxed at 12.5% without indexation on gains above the annual exemption.
Annual LTCG exemption
₹1.25 L
The first ₹1.25 lakh of long-term equity gains in a financial year is tax-free, across all equity funds and shares combined.
Rates as applicable to resident individuals for FY 2026-27 under the current capital gains regime. Surcharge and cess apply on top. One point specific to this category: healthcare rallies are often event-driven — an approval, a resolved inspection — and selling into one frequently lands inside the 12-month window, where the rate is 20%. Tax rules change; confirm your position with a tax adviser.
Terms you will meet on a healthcare fund factsheet
- ANDA
- Abbreviated new drug application — the filing route for a generic drug in the United States. Filings and approvals indicate the future revenue pipeline.
- Warning letter / import alert
- USFDA actions following an inspection. An import alert blocks products from that plant entering the US until issues are fixed.
- Price erosion
- The annual decline in generic drug prices in a competitive market. The headwind every US-facing pharma company runs against.
- Complex generics
- Injectables, inhalers, dermatology and specialty formulations. Fewer competitors, better margins, harder approvals.
- CDMO
- Contract development and manufacturing organisation — making drugs or intermediates for other companies, a fast-growing Indian export segment.
- NLEM / price control
- The national list of essential medicines, which caps prices of listed drugs in the domestic market.
- ARPOB
- Average revenue per occupied bed — the core profitability measure for a hospital chain, alongside occupancy.
- Top-ten weight
- The share of the fund in its ten largest holdings. In healthcare funds this is usually 55-70%, far higher than a diversified fund.
Frequently asked questions
What is a healthcare mutual fund?
A sectoral or thematic equity scheme that must keep at least 80% of its assets in healthcare companies — pharmaceutical manufacturers, contract manufacturing and research organisations, hospital chains, diagnostics laboratories, medical devices and sometimes health insurers. The remaining 20% is at the manager’s discretion.
Which are the best healthcare funds in India?
The funds differ mainly in how much sits in export generics versus domestic services. Nippon India Pharma and UTI Healthcare are pharma-weighted. ICICI Prudential Pharma Healthcare & Diagnostics, SBI Healthcare Opportunities and Mirae Asset Healthcare read the theme more widely and hold hospitals and diagnostics. DSP Healthcare keeps a global sleeve. Decide which exposure you want, then compare rolling returns, expense ratio, concentration and manager tenure within that group.
Are healthcare funds a good investment in 2026?
The structural case is solid: India is short of hospital beds, diagnostics penetration is low, and Indian manufacturers supply a large share of the world’s generic medicines. The counterpoint is that the category has already had a strong three-year run, service-side valuations are high, and a regulatory action can undo a year of gains overnight. A 5-10% satellite position is the sensible size.
How much of my portfolio should be in healthcare funds?
Cap any single sector or thematic fund at 5 to 10% of your equity allocation. Diversified and index funds already hold 5-7% in pharma, so a sector fund is added exposure on top of what you own rather than new exposure.
How are healthcare funds taxed in India?
As equity-oriented schemes. Units held 12 months or less are taxed at 20% as short-term capital gains. Units held longer are taxed at 12.5% as long-term capital gains, with the first ₹1.25 lakh of long-term equity gains in a financial year exempt across all your equity holdings combined. A fund with a large overseas allocation may not qualify as equity-oriented — check the scheme document.
What returns do healthcare funds give?
Better than most people expect and less smoothly. The category had a poor stretch from 2015 to 2019 as US pricing collapsed and compliance problems mounted, then a strong recovery. Over a full cycle, mid-teens is a reasonable expectation, with the return arriving in concentrated bursts.
Pharma fund or healthcare fund?
A pharma fund is mostly drug manufacturers, weighted to exports. A healthcare fund adds hospitals, diagnostics and devices, which are domestic, service-based and less exposed to foreign regulators. If you want the India demand story rather than the export margin cycle, the broader healthcare mandate is closer to it.
Wondering how much healthcare exposure you already have?
Pharma is a meaningful part of every diversified fund. Talk to a Dhan Saarthi advisor — twenty minutes on your existing portfolio, horizon and tax position, and you will know whether a healthcare fund adds anything or just doubles up.
Disclaimer
Mutual fund investments are subject to market risk. Read all scheme related documents carefully before investing. Past performance is not indicative of future results, and the value of your investment can go down as well as up.
Sectoral and thematic funds carry concentration risk and are meant for investors who understand that a single sector can underperform the broader market for extended periods. This page is educational content on a fund category, not investment advice or a recommendation to buy or sell any specific scheme.
Dhan Saarthi is a mutual fund distribution platform. Fund selection should reflect your own goals, horizon, tax position and risk tolerance. Consider consulting a SEBI-registered investment adviser before acting on anything here. Scheme names are mentioned for illustration and are not endorsements.
Tax rates referenced apply to resident individual investors under the capital gains regime in force at the date of publication and may change. Returns shown are illustrative placeholders, not live NAV-based figures. Calculator outputs are arithmetic projections based on the assumptions you enter, not guarantees.